Renewable share of electricity generation
33%Global, 2025
+3 ppsince 2023
Source: IEA
WLD · World total · 73 publishers
Global statistics
1,840 verified figures for Global across 22 industries and 1,136 measures, 1990–2089, from 73 publishers.
Global, August 2026
+1.7%since July 2026
Source: FAO
Amazon cloud infrastructure services market share
28%Global, Q2 2026
0 ppsince Q1 2026
Source: Synergy Research
Phase I small molecule clinical trial share
62%Global, 2025
+2 ppsince 2023
Source: IQVIA
Key findings
Drawn from every industry that publishes a figure for Global.
Market size and output 4
- Semiconductor sales worldwide were 791.7 billion USD in 2025 (SIA). SIA ↗ T2 Official
- Total spending on electric cars worldwide was about 860 billion USD in 2025 (IEA). IEA ↗ T1 Official
- Semiconductor materials market revenue worldwide was 73.2 billion USD in 2025 (SEMI). SEMI ↗ T2 Official
- Semiconductor sales of logic products worldwide were 301.9 billion USD in 2025 (SIA). SIA ↗ T2 Official
Capacity and infrastructure 3
- Global Nominal Crude Steelmaking Capacity was 2,445 million million tonnes in 2025 (OECD). OECD ↗ T1 Official
- Global Steel Excess Capacity Volume was 640 million million tonnes in 2025 (OECD). OECD ↗ T1 Official
- Value of cancelled polysilicon and wafer manufacturing capacity projects worldwide was about 25 billion USD in 2024 (IEA). IEA ↗ T1 Official
Trade 2
Other measures 1
- Global Airport Passenger Throughput was 9.8 billion passengers in 2025 (ACI World). ACI World ↗ T1 Official
Global by industry
Every measure published for Global, grouped by industry, with its latest value and
trend. Region code GLOBAL is the same in every industry and in the API.
Electricity and Gas Utilities 244
Show 239 more measures
- Coal-fired electricity generation growth 1.3%
- Power sector CO2 emissions growth 1.2%
- Renewables share of heat consumption 10%
- Power generation CO2 emissions growth rate 1%
- Share of renewables in final energy consumption 13%
- Share of top supplier in rare earth refining 85%
- Wind and solar share of electricity generation 15%
- Average annual electricity demand growth 2.6%
- Battery storage price 1.02 million USD per MW
- Carbon intensity of electricity generation 445 gCO2/kWh
- Clean energy technology trade measures 200
- CO2 emissions intensity of electricity generation 445 g CO2/kWh
- Coal share of electricity generation 33%
- Cumulative wind capacity installed 1 terawatts
- Electricity consumption 28,600 terawatt-hours
- Electricity generation CO2 emissions annual change rate 1.2%
- Energy transition investment 2.3 trillion USD
- Global data centre electricity consumption, IEA April 2026 vintage 485 TWh
- Hybrid drive wind turbine market share 37%
- Low-emissions sources share of electricity generation 41%
- Nuclear electricity generation growth 2.5%
- Renewable electricity generation growth 8%
- Renewable energy investment 2.2 trillion USD
- Renewable energy investment growth rate 7.3%
- Renewable heat consumption growth rate 20%
- Renewable power generation capacity 4,250 GW
- Renewables share in road transport 4%
- Renewables share of net new power capacity 66.7%
- Renewables share of power demand 24%
- Renewables share of transport energy demand 3.4%
- Share of renewable capacity expansion driven by competitive auctions 20%
- Solar panel price 0.18 million USD per MW
- Solar PV share of renewable capacity growth 80%
- Wind power share of global electricity demand 10%
- Wind turbine price 0.8 million USD per MW
- Accelerated case additional renewable capacity 1,150 gigawatts
- Accelerated case renewable capacity growth boost 30%
- Accelerated case renewable capacity growth premium 26%
- Additional connections enabled by selected grid technologies: upper potential 330 GW
- AI-focused data centres: annual electricity consumption growth 50%
- All data centres: annual electricity consumption growth 17%
- Annual end-of-life solar PV panel volume 25 million tonnes
- Annual renewable capacity additions forecast for 2030 940 billion watts
- Annual solar capacity additions 425 GW
- Annual wind turbine capacity installed by Envision 21.8 GW
- Annual wind turbine capacity installed by Goldwind 29.7 GW
- Annual wind turbine capacity installed by Mingyang 18.6 GW
- Annual wind turbine capacity installed by SANY 15.1 GW
- Annual wind turbine capacity installed by Windey 19.8 GW
- Auctioned renewable capacity growth rate 15%
- Auctions and green certificate schemes coverage of capacity expansion 60%
- Average offshore wind turbine size 10,312 kW
- Average onshore wind turbine size 6,160 kW
- Avoided carbon dioxide emissions from renewable power generation 8.4 gigatonnes
- Bioenergy share of electricity demand 3%
- Bioenergy share of renewable consumption growth 30%
- Biofuel output growth rate 25%
- Biofuels production growth forecast 16%
- Biofuels share of renewable energy consumption in road transport 90%
- Cancelled polysilicon manufacturing capacity projects 300 billion watts
179 further measures are in the Electricity and Gas Utilities page.
Pharmaceuticals 198
Cell and gene therapy venture capital and public funding deal count 96 −1% since 2022 IQVIA 3 records
Show 193 more measures
- Cardiometabolic RNA and next-generation lipid drug trial starts 128
- Gene editing trial starts 133
- GLP-1, incretin multi-agonist and amylin trial starts 798
- Inflammatory bowel disease drug trial starts 373
- KRAS and RAS inhibitor trial starts 226
- Oncology bispecific antibody trial starts 985
- Radioligand therapy trial starts 291
- Large company small molecule share of Phase I clinical trial starts 66%
- Novel active substance launches 79
- Cell and gene therapy clinical trial starts 631
- Cell and gene therapy venture funding deal count year-over-year change -24%
- Common new active substance approvals across major regulatory authorities (multi-year total) 52
- First-in-class novel active substance launches 30
- Medicine use compound annual growth rate 2.7%
- Oncology clinical trial starts growth rate -4%
- Per capita medicine use compound annual growth rate 1.9%
- Phase I immunology clinical trial starts growth rate -13%
- Phase II immunology clinical trial starts growth rate 14%
- Phase II oncology clinical trial starts growth rate 3%
- Phase III immunology clinical trial starts growth rate -4%
- Phase III oncology clinical trial starts growth rate 4%
- Active Alzheimer's disease drug trials 280
- Active antibody-drug conjugate trials 1,488
- Active autoimmune cell therapy and T-cell engager trials 279
- Active cardiometabolic RNA and next-generation lipid drug trials 90
- Active gene editing trials 131
- Active GLP-1, incretin multi-agonist and amylin trials 600
- Active inflammatory bowel disease drug trials 372
- Active KRAS and RAS inhibitor trials 217
- Active oncology bispecific antibody trials 1,109
- Active radioligand therapy trials 323
- Annual net sales growth guidance at constant exchange rates 10%
- Antibody-drug conjugate trial starts since 2023: Breast cancer 315
- Antibody-drug conjugate trial starts since 2023: Gastric or oesophageal cancer 121
- Antibody-drug conjugate trial starts since 2023: Lung cancer 193
- Antibody-drug conjugate trial starts since 2023: Lymphoma 119
- Antibody-drug conjugate trial starts since 2023: Ovarian, cervical or endometrial cancer 195
- Antibody-drug conjugate trial starts since 2023: Urothelial or bladder cancer 116
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Immune thrombocytopenia or autoimmune haemolytic anaemia 26
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Multiple sclerosis 25
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Myasthenia gravis 29
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Systemic lupus erythematosus / lupus nephritis 147
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Systemic sclerosis 68
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Vasculitis 39
- Cell and gene therapy share of medicine spending 0.4%
- Cell and gene therapy spending 5.9 billion USD
- Cell and gene therapy spending average annual growth rate 65%
- Cell and gene therapy spending share by geography 38%
- Cell and gene therapy spending year-over-year growth 38%
- Cell and gene therapy venture capital and public funding deal value 3.4 billion USD
- Company countries of operation 150
- Contact lens wearers 140 million
- Countries with drug approval 90
- Cumulative cell and gene therapy launches 76
- Dupixent sales 5.2 billion EUR
- Expected annual novel active substance launches (lower bound) 70
- Expected annual novel active substance launches (upper bound) 80
- Expected cumulative novel active substance launches (lower bound) 350
- Expected cumulative novel active substance launches (upper bound) 400
- Gene editing trial starts since 2023: Cancer 36
133 further measures are in the Pharmaceuticals page.
Food and Beverage 130
Vegetable oil price index month-on-month growth rate (monthly) 1.1% −0.9 pp since July 2026 FAO 6 records
Show 125 more measures
- Dairy price index month-on-month growth rate (monthly) 2.3%
- Sugar price index month-on-month growth rate (monthly) 11.9%
- Cereal price index year-on-year growth rate (monthly) 6.9%
- Meat price index month-on-month growth rate (monthly) 1%
- All rice price index month-on-month growth rate (monthly) 3.2%
- Cereal production 3,043 million tonnes
- Cereal stocks-to-use ratio 31.9%
- Cereal production annual growth rate 6.1%
- Wheat production 810.9 million tonnes
- Wheat production annual growth rate -4.3%
- Cereal trade volume 509.3 million tonnes
- Cereal ending stocks 957.8 million tonnes
- Cereal utilization annual growth rate 2.7%
- Cereal trade annual growth rate 4.8%
- Sugar consumption 180.4 million tonnes
- Cereal harvested area growth rate 0.5%
- Cereal stocks annual growth rate 9.5%
- Cereal utilization 2,965 million tonnes
- Food price index two-month growth rate 5%
- ISA daily raw sugar price (monthly) 17.4 cents/lb
- Maize production 1,309 million tonnes
- Rice trade volume 61.7 million tonnes
- Share of cereal production traded 17%
- Share of feed use in cereal consumption 34%
- Share of food use in cereal consumption 40%
- Share of other coarse grains used for feed 56%
- Share of other coarse grains used for food 27%
- Sugar consumption annual growth rate 0.39%
- Sugar consumption increase 0.8 million tonnes
- Sugar price index year-on-year growth rate (monthly) -21.2%
- Sugar supply-demand balance -3.2 million tonnes
- Wheat price month-on-month growth rate (monthly) 2.6%
- Wheat price year-on-year growth rate (monthly) 15%
- Agricultural and fisheries production growth 13%
- Agricultural price index growth rate -2%
- Aquaculture production growth rate 2.9%
- Aquaculture share of total fisheries and aquaculture production 56%
- Aquaculture share of total fisheries and aquaculture production (snapshot) 53%
- Beverage price index growth rate -7%
- Cereal consumption 3.25 billion tonnes
- Cereal consumption growth rate 12%
- Cereal harvested area 763 million hectares
- Cereal harvested area increase 15 million hectares
- Cereal price index 116.3 points
- Cereal price index growth rate (monthly) 2.2%
- Cereal yield 4.2 tonnes per hectare
- Cereal yield growth rate 0.9%
- Cheese price growth rate (monthly) 2.7%
- Coarse grain production 1,619 million tonnes
- Dairy price index 119.2 points
- Dairy price index growth rate (annual) -21.7%
- Dairy price index growth rate (monthly) 2.3%
- Dry beans trade volume 5.2 million tonnes
- Dry beans trade volume growth rate 1%
- Fisheries and aquaculture production 200.5 million tonnes
- Fisheries and aquaculture production growth 11%
- Food cereal consumption growth rate 1%
- Food commodity price index growth 2.5%
- Food import bill 2.22 trillion USD
- Food import bill growth rate in low-income countries 6.7%
65 further measures are in the Food and Beverage page.
Software and IT Services 84
Combined monthly active user accounts of Weixin and WeChat 1,439 million +0.5% since 31 Mar 2026 Tencent 8 records
Cloud infrastructure services quarterly revenue 143.4 billion USD +12% since Q1 2026 Synergy Research 6 records
Show 79 more measures
- Google cloud infrastructure services market share 15%
- Microsoft cloud infrastructure services market share 20%
- Public cloud market share of top three providers 67%
- Public IaaS and PaaS revenue year-on-year growth rate 47%
- IC3 Business Email Compromise complaints 24,768
- IC3 extortion complaints 89,129
- IC3 extortion reported losses 122,499,133 USD
- IC3 government impersonation fraud complaints 32,424
- IC3 government impersonation fraud reported losses 797,943,193 USD
- IC3 investment fraud complaints 72,984
- IC3 investment fraud reported losses 8,648,617,756 USD
- IC3 personal data breach complaints 67,456
- IC3 phishing and spoofing complaints 191,561
- IC3 phishing and spoofing reported losses 215,843,126 USD
- IC3 ransomware incident complaints 3,611
- IC3 ransomware reported losses 32,320,105 USD
- IC3 tech and customer support fraud complaints 47,794
- OpenAI annualized recurring revenue (ARR) 20,000,000,000 USD
- Top three cloud providers combined infrastructure services market share 63%
- Cloud infrastructure services trailing twelve-month revenue 500 billion USD
- ChatGPT gender-identifiable users with feminine names share 52%
- ChatGPT weekly active users (WAU) 700,000,000 users
- Cloud infrastructure services spending year-on-year growth rate 43%
- Enterprise on-premise share of total data center capacity 56%
- Generative AI tools weekly usage across six markets 34%
- Hyperscale data centers in future pipeline (snapshot) 915
- Neocloud revenue growth 223%
- Operational hyperscale data centers 1,360
- Top three cloud providers share of hyperscale data center capacity 57%
- Amazon cloud infrastructure services market share (annual) 32%
- Amazon share of cloud infrastructure services market 30%
- Anthropic Claude 3.5 Sonnet API input price 3 USD
- Anthropic Claude 3.5 Sonnet API output price 15 USD
- Businesses using OpenAI products 2,500,000 organizations
- ChatGPT consumer messages: Asking share 49%
- ChatGPT consumer messages: Doing share 40%
- ChatGPT consumer messages: Expressing share 11%
- ChatGPT consumer usage: Non-work share 70%
- ChatGPT consumer usage: Work-related share 30%
- Cloud infrastructure services market revenue 419 billion USD
- Cloud infrastructure services market revenue constant currency growth rate 30%
- Cloud infrastructure services spending sequential growth (quarterly) 7.5 billion USD
- Colocation share of total data center capacity 20%
- Developer performance improvement from automation at work 43%
- Developer performance improvement from automation in open source 27%
- Developer productivity increase with good documentation 55%
- Enterprise on-premise share of total data center capacity (quarterly) 32%
- FBI IC3 annual cybercrime complaints 1,008,597
- FBI IC3 annual cybercrime losses 20.9 billion USD
- GenAI-specific cloud services year-on-year growth rate 165%
- GitHub Copilot adoption growth among students, teachers and open source maintainers 100%
- GPU-as-a-service revenue annual growth rate 200%
- GPUaaS and GenAI platform services revenue growth 165%
- Hyperscale data centers in future pipeline 803
- Hyperscale operator capital expenditure (quarterly) 142 billion USD
- Hyperscale share of total data center capacity 48%
- Hyperscale share of total data center capacity (annual) 67%
- IC3 Business Email Compromise reported losses 3,046,598,558 USD
- IC3 personal data breach reported losses 1,314,923,988 USD
- IC3 tech and customer support fraud reported losses 2,134,675,818 USD
19 further measures are in the Software and IT Services page.
Telecommunications 96
Show 91 more measures
- 5G subscriptions 3.3 billion
- 4G networks deployed 838
- 5G share of mobile data traffic 48%
- Cellular IoT connections 4.5 billion
- Data-only mobile broadband basket price as share of GNI per capita 1.4%
- Fixed broadband traffic 5.1 zettabyte
- Internet penetration divide between developed and least developed countries 63 percentage points
- Mobile broadband subscriptions per 100 inhabitants 99 per 100 inhabitants
- Mobile broadband traffic 1.3 zettabyte
- Mobile data traffic (exabytes per month, excluding FWA) 146 exabytes
- Mobile industry contribution to GDP 7.6 trillion USD
- Mobile network data traffic including FWA (exabytes per month) 203 exabytes
- Mobile phone ownership rate 80%
- Mobile-cellular subscriptions 9.2 billion
- New mobile internet users (annual) 160 million
- Population without mobile broadband network coverage 312 million
- 2G subscription decline 23 million
- 3G subscription decline 18 million
- 4G (LTE) subscriptions 4.5 billion
- 4G population coverage 93%
- 4G subscription decline 62 million
- 5G mid-band population coverage outside mainland China 45%
- 5G population coverage, high-income countries 84%
- 5G population coverage, low-income countries 4%
- 5G population coverage, rural areas 40%
- 5G population coverage, urban areas 66%
- 5G share of mobile broadband subscriptions 36%
- 5G standalone subscriptions 3.9 billion
- 5G subscription growth 155 million
- 5G subscriptions added during the year 660 million
- 6G subscriptions 180 million
- Active mobile money accounts (30-day) 593 million
- Commercial 5G standalone network slicing offerings 84
- Economies meeting the mobile broadband affordability target 130
- Entry-level handset cost as share of income (poorest quintile) 44%
- Female mobile phone ownership rate 77%
- Fixed broadband basket price as share of GNI per capita 2.5%
- Fixed broadband subscriptions 2 billion
- Fixed broadband subscriptions per 100 inhabitants 20 per 100 inhabitants
- Fixed broadband subscriptions per 100 inhabitants, high-income countries 39 per 100 inhabitants
- Fixed broadband subscriptions per 100 inhabitants, low-income countries 0.6 per 100 inhabitants
- Fixed broadband traffic annual growth rate 15.2%
- Fixed wireless access connections on mobile networks 350 million
- GDP gain from closing mobile usage gap 3.5 trillion USD
- Gender gap among non-owners of mobile phones 35%
- Gender parity score for Internet use 0.92
- Gender parity score for mobile phone ownership 0.9 ratio
- Gender parity score in Internet use 0.94 ratio
- Gender parity score in mobile phone ownership 0.93 ratio
- International Internet bandwidth 1.83 million Gbps
- International Internet bandwidth growth 23%
- Internet penetration rate in developed economies 90%
- Internet penetration rate in least developed countries 27%
- Internet use penetration rate 74%
- Internet use penetration rate, high-income countries 94%
- Internet use penetration rate, low-income countries 23%
- Internet use rate, men 77%
- Internet use rate, population aged 15-24 82%
- Internet use rate, rural areas 58%
- Internet use rate, urban areas 85%
31 further measures are in the Telecommunications page.
Semiconductors 80
Semiconductor sales, three-month moving average 146.8 billion USD +6.5% since June 2026 SIA 3 records
Semiconductor equipment billings growth rate (year-over-year) 23% +12 pp since Q3 2025 SEMI 3 records
Show 75 more measures
- Semiconductor sales (annual) 795.6 billion USD
- Advanced-node wafer capacity (7nm and below) 850 thousand wafers per month
- Foundry revenue (quarterly) 46.3 billion USD
- Semiconductor equipment billings 135.1 billion USD
- Semiconductor sales growth (annual) 25.6%
- Semiconductor sales growth rate (year-over-year) 37.1%
- Semiconductor sales of logic products 301.9 billion USD
- Semiconductor sales of memory products 223.1 billion USD
- Worldwide semiconductor equipment quarterly billings 40.5 billion USD
- Analog annual sales growth, spring 2026 forecast 10%
- ASML gross margin 52.8%
- ASML research and development expenditure 4.7 billion EUR
- ASML total net sales 32.7 billion EUR
- ASML total net sales (forecast) 39 billion EUR
- Assembly and packaging equipment sales growth rate 21%
- Assembly and packaging equipment sales, July 2026 forecast 6.7 billion USD
- Capital expenditure on advanced-process semiconductor equipment 50 billion USD
- Combined annual revenue of the world's top ten foundries 169.5 billion USD
- Combined market share of five largest foundries 80%
- Combined wafer cleaning equipment market share of Screen, Tokyo Electron and Lam Research 75%
- Conventional DRAM contract price growth forecast (lower bound) 58%
- Conventional DRAM contract price growth forecast (upper bound) 63%
- Discrete semiconductors annual sales growth, spring 2026 forecast 8%
- DRAM industry revenue (quarterly) 97 billion USD
- DRAM sales growth 82.6%
- Global semiconductor annual sales growth, spring 2026 forecast 90%
- Global semiconductor annual sales, spring 2026 forecast 1.51 trillion USD
- GlobalFoundries quarterly revenue 1.8 billion USD
- Logic annual sales growth, spring 2026 forecast 37%
- Logic semiconductor sales 212.6 billion USD
- Logic semiconductor sales growth rate 39.9%
- Memory annual sales growth, spring 2026 forecast 250%
- Memory semiconductor sales 165.1 billion USD
- Memory semiconductor sales growth rate 34.8%
- NVIDIA automotive and robotics revenue (fiscal year) 2.3 billion USD
- NVIDIA data center revenue 62.3 billion USD
- NVIDIA data center revenue (fiscal year) 193.7 billion USD
- NVIDIA quarterly revenue outlook 78 billion USD
- Samsung Device Solutions (semiconductor) division revenue 44 trillion KRW
- Samsung Electronics quarterly revenue 93.8 trillion KRW
- Samsung Electronics research and development expenditure 37.7 trillion KRW
- Samsung first-generation 2nm mass production 1
- Semiconductor equipment billings (quarterly) 33.7 billion USD
- Semiconductor equipment billings (year-to-date) (year to date) 100 billion USD
- Semiconductor equipment billings growth rate (quarter-over-quarter) 2%
- Semiconductor equipment billings growth rate (year-over-year) (annual) 15%
- Semiconductor materials market revenue 73.2 billion USD
- Semiconductor memory sales growth 78.9%
- Semiconductor sales (quarterly) 403.3 billion USD
- Semiconductor sales growth in computer applications 60%
- Semiconductor sales growth rate (quarter-over-quarter) 35.1%
- Semiconductor sales growth rate, three-month moving average (year-over-year) 135.1%
- Semiconductor sales of automotive integrated circuits 42.2 billion USD
- Semiconductor sales of microcontroller units 27.9 billion USD
- Semiconductor test equipment billings growth 55%
- Semiconductor test equipment sales, July 2026 forecast 15.3 billion USD
- Silicon wafer revenue 11.4 billion USD
- Silicon wafer revenue growth rate -1.2%
- Silicon wafer shipment growth rate 5.8%
- Silicon wafer shipment growth rate (quarterly) 7.4%
15 further measures are in the Semiconductors page.
Electric Vehicles 67
Show 62 more measures
- Electric three-wheeler sales share 21%
- Electric trucks as a share of truck sales 9%
- Electric vehicle battery deployment 1,200 GWh
- Lithium-ion battery pack price change -14%
- Average LFP battery pack price 81 USD
- Average lithium-ion battery pack price 108 USD
- Average lithium-ion battery pack price 115 USD/kWh
- Average lithium-ion battery pack price for battery electric vehicles 97 USD/kWh
- Average NMC battery pack price 128 USD
- Battery recycling capacity 300 gigawatt-hours
- BYD EV battery energy usage 134.4 GWh
- CATL EV battery energy usage 289.3 GWh
- Commissioned battery-cell manufacturing capacity 3,100 GWh
- Consumer spending on electric cars 560 billion USD
- Electric bus sales 50,000
- Electric bus sales share 3%
- Electric bus stock 635,000
- Electric car fleet in circulation 58 million
- Electric car production 22 million
- Electric car sales (quarterly) 4 million
- Electric car sales (weekly) 250,000
- Electric car sales growth (quarterly) 25%
- Electric car sales growth rate 20%
- Electric car sales growth rate (quarterly) 35%
- Electric car trade growth 20%
- Electric light commercial vehicle driving range 170 km
- Electric light commercial vehicle sales growth 50%
- Electric light commercial vehicle sales share 4%
- Electric share of vehicles sold 66.7%
- Electric three-wheeler sales 1 million
- Electric three-wheeler sales growth rate 30%
- Electric truck sales 54,000
- Electric truck sales growth rate 35%
- Electric two- and three-wheeler sales share 13%
- Electric vehicles as a share of total electricity demand 2.5%
- Electricity consumption of the electric vehicle fleet 367,000 GWh
- EV battery demand 750 gigawatt-hours
- EV battery demand growth multiple by 2035 7 times
- EV battery energy usage (SNE Research) 785.6 GWh
- EV battery energy usage growth rate 26.4%
- EV battery manufacturing capacity 2.2 terawatt-hours
- Fast charger share of public charging stock (snapshot) 35%
- Fast EV charger growth rate 55%
- Global Electric Car Q1 Sales Growth 35%
- Global Electric Truck Sales Growth 80%
- Growth in EV battery deployment 30%
- Lithium-iron-phosphate share of EV sales by battery capacity 40%
- Number of car manufacturers with electrification targets 20
- Oil demand avoided by EV uptake 6 million barrels per day
- Public charging points 5 million
- Public charging points added 1.3 million
- Public EV charging stock growth rate 40%
- Public fast charging points 2 million
- Ratio of announced battery recycling capacity to recyclable battery supply 3 times
- Required growth multiple for heavy-duty charging capacity by 2035 20 times
- Required growth multiple for public charging by 2035 6 times
- Share of available electric models that are large vehicles 66.7%
- Share of car sales by manufacturers with electrification targets 90%
- Share of investment announcements committed 40%
- Three-wheeler sales (all powertrains) 4.5 million
2 further measures are in the Electric Vehicles page.
Information Services 20
Show 15 more measures
- AI as main source of news 1%
- AI chatbot weekly usage for news among adults under 35 16%
- Click-through frequency from AI chatbots to original news sources 42%
- Exclusively using social media and video networks for news 12%
- Facebook usage for news 43%
- Instagram usage for news 26%
- Instagram usage for news among young adults aged 18–24 42%
- News websites and apps as online news source 51%
- Overall trust in news 37%
- Social media and video networks as main source of news 30%
- Social media and video networks as online news source 54%
- TikTok usage for news 20%
- Trust in news from AI chatbots 20%
- X (formerly Twitter) usage for news among young adults aged 18–24 15%
- YouTube usage for news 34%
Insurance 44
Show 39 more measures
- ERGO International net result 541 million EUR
- ERGO operating result 1,405 million EUR
- ERGO total technical result 2,282 million EUR
- Global Specialty Insurance combined ratio 85.9%
- Global Specialty Insurance net result 562 million EUR
- Global Specialty Insurance revenue 8,625 million EUR
- Life insurance premiums 3.1 trillion USD
- Life insurance savings premium cumulative growth 300 billion USD
- Mortality insurance resilience index 44.4%
- Natural catastrophe economic losses (year to date) 112 billion USD
- Non-life insurance investment yield 3.9%
- Total insurance protection gap 1.83 trillion USD
- Catastrophe bond market capital 50 billion USD
- Crop insurance protection gap 77 billion USD
- Crop insurance resilience index 43.5%
- Disaster protection gap 181 billion USD
- Global Specialty Insurance combined ratio forecast 90%
- Health insurance protection gap 941 billion USD
- Health insurance protection gap growth 5.4%
- Health insurance resilience index 77.7%
- Insurance resilience index 58%
- Life insurance assets transferred to private equity insurers 1 trillion USD
- Life insurance profitability growth 15%
- Life insurance savings premiums 4 trillion USD
- Life insurance savings real premium growth rate 1.1%
- Life insurer operating result growth 60%
- Mortality insurance protection gap 414 billion USD
- Natural catastrophe insurance coverage rate 40%
- Natural catastrophe insurance protection gap 385 billion USD
- Natural catastrophe insurance protection gap growth 5.2%
- Natural catastrophe insurance resilience index 25.7%
- Severe convective storm insured losses (year to date) 64 billion USD
- Total insurance protection gap compound annual nominal growth rate 3.6%
- Total insurance protection gap nominal growth rate 3.1%
- Traditional reinsurance capital 500 billion USD
- Underlying return on equity target (lower bound) 14%
- Underlying return on equity target (upper bound) 16%
- Uninsured disaster loss share (annual) 57%
- Uninsured disaster loss share (year to date) 60%
Airlines and Air Transport 49
Show 44 more measures
- Airline industry revenue 958.4 billion USD
- Air cargo capacity (ACTK) growth 3.7%
- Airline available seat kilometre (ASK) growth 5.2%
- Airline industry net profit 41 billion USD
- Airline RPK growth 5.3%
- Commercial aircraft deliveries 1,114
- Domestic airline RPK growth 2.4%
- Domestic share of airline RPK 37.2%
- Fuel share of airline operating costs 25.7%
- International airline revenue passenger kilometre (RPK) growth 7.1%
- Air cargo demand growth on the Europe-Asia trade lane 10.3%
- Air cargo load factor 45.9%
- Air cargo yield change -1.5%
- Airbus commercial aircraft deliveries 766
- Airbus commercial aircraft order backlog 8,658
- Airbus commercial aircraft revenue 50.6 billion EUR
- Airbus consolidated net income 4.23 billion EUR
- Airbus consolidated revenue 69.2 billion EUR
- Airbus gross commercial aircraft orders 878
- Airbus total employees 156,921
- Airline ancillary revenue 144 billion USD
- Airline cargo revenue 142 billion USD
- Airline direct employment 3.3 million
- Airline industry net profit margin 3.7%
- Airline industry operating profit 66 billion USD
- Airline industry return on invested capital (ROIC) 6.7%
- Airline passenger revenue 693 billion USD
- Airline revenue passenger kilometres (RPK) 9,098 billion passenger km
- Airlines with zero flight cancellations 7
- Average jet fuel price 86 USD/barrel
- Aviation accident rate 2.56
- Boeing 787 deliveries 51
- Commercial aircraft net orders 1,380
- Commercial aircraft order backlog 17,000
- Europe-Asia Corridor Passenger Traffic Growth 12.1%
- Global Aircraft Movements 103.1 million
- Global Airline Capacity Growth (ASK) 0.3%
- Global Airline Passenger Demand Growth (RPK) 0.2%
- Global Airport First-Half Passenger Volume 4.7 billion passengers
- Global Airport Passenger Throughput 9.8 billion passengers
- Global Domestic Passenger Demand Growth 0.6%
- Global Passenger Load Factor 85.2%
- International airline passenger load factor 83.2%
- Top 20 LCC market share by arrivals volume 82%
Oil and Gas 25
Show 20 more measures
- Oil demand growth 2.5 million barrels per day
- Oil inventory drawdown 3.9 million barrels per day
- Upstream oil and gas capital expenditure growth -25%
- Liquefied natural gas supply change 40 bcm
- Liquefied natural gas supply growth rate 7%
- Oil production capacity growth 5 million barrels per day
- Brent crude oil price annual change -11 USD per barrel
- Brent crude oil spot price (monthly) 91 USD per barrel
- Brent crude oil spot price (quarterly) 77 USD per barrel
- Brent crude oil spot price (USD per barrel) 69 USD per barrel
- Brent crude oil spot price change (monthly) 7 USD per barrel
- Crude oil price month-over-month change 7 USD per barrel
- Crude oil spot price 91 USD per barrel
- Energy consumption growth 50%
- Natural gas price growth rate -20%
- Oil demand displaced by electric vehicles 5.4 million barrels per day
- Oil production capacity 114.7 million barrels per day
- Refining capacity additions 7.7 million barrels per day
- Share of global oil supply disrupted 10%
- Spare capacity share of demand 2.2%
Film and Video 9
Show 4 more measures
Healthcare 26
Oncology novel active substance (NAS) launches (cumulative) 132 +67% since 2015–2019 IQVIA 3 records
Show 21 more measures
- AMR-driven annual global GDP reduction 3.8%
- Cell and gene therapy spending growth rate 38%
- Childhood cancer medicines lacking child-friendly formulations 6
- Global Initiative for Childhood Cancer beneficiaries 500,000
- Global Initiative for Childhood Cancer country coverage 90
- Global Platform participating countries 12
- Global Platform participating governments 12
- Market shaping strategy interventions 10
- Novel active substance launches, five-year total 388
- Novel active substance launches, five-year total (excluding COVID-19 products) 369
- Novel modality share of oncology trials 35%
- Oncology medicine spending growth (5-year) 75%
- Oncology medicine spending growth (annualized) 11.9%
- Phase I share of oncology trials 38%
- Phase II share of oncology trials 48%
- Phase III share of oncology trials 14%
- Rare cancer share of oncology trial starts 74%
- Share of human rabies transmissions caused by dogs 99%
- Share of Pharmerging market pharmaceutical spending growth from top eight countries 83%
- WHO operational locations 150
- WHO presence locations 150
Steel and Basic Metals 19
Show 14 more measures
- Bulgaria Basic Metals Share of Sold Production Value 22%
- Capacity utilisation 76%
- Global Monthly Crude Steel Production 144.2 million million tonnes
- Global Monthly Crude Steel Production Growth -1.2%
- Global Nominal Crude Steelmaking Capacity 2,445 million million tonnes
- Global Steel Excess Capacity Projection 2028 745 million million tonnes
- Global Steel Excess Capacity Volume 640 million million tonnes
- Reporting Countries Share of World Steel Production 98%
- Stainless steel melt shop production 33 million tonnes
- Stainless steel melt shop production (year to date) 33 million tonnes
- Stainless steel melt shop production growth 5%
- Stainless steel melt shop production growth (year to date) 5%
- Steel demand shortfall 60 million tonnes
- Worldsteel Member Global Production Share 85%
Chess 17
Show 12 more measures
- Female share of FIDE standard-rated players 11.1%
- FIDE active standard-rated players 220,503
- FIDE female players rated 2200+ 746
- FIDE players rated 2200+ 20,574
- FIDE players rated 2400+ 2,958
- FIDE players rated 2500+ 850
- FIDE players rated 2700+ 35
- FIDE rated juniors (born 2008 or later) 122,176
- FIDE Woman Grandmasters (standard list) 539
- Inactive share of FIDE standard-rated players 61.1%
- Median FIDE standard rating 1,710 Elo
- Share of rated players in the five largest federations 38%
Shipping and Water Transport 13
Show 8 more measures
- Dual-fuel container ships and vehicle carriers year-over-year growth rate 65%
- Dual-fuel share of container ship orders 78%
- Hapag-Lloyd fleet transport capacity 2.5 million TEU
- Liner shipping investment in renewable fuel ships 160 billion EUR
- Private investment in dual-fuel container ships and vehicle carriers 180 billion USD
- Share of containers lost at sea 0.0005%
- Sustainable maritime fuel cost premium (maximum) 400%
- Sustainable maritime fuel cost premium (minimum) 100%
Hotels and Accommodation 5
Retail 4
Fitness and Sports 2
Chemicals 2
Population 1
Broadcasting 1
1136 measures. Each name opens the full series; each value opens the record with its source evidence.
Sources
| Document | Publisher | Authority tier | Published | Accessed | Locator | Data points |
|---|---|---|---|---|---|---|
| Global airport passenger traffic reaches record 9.8 billion in 2025, Airports Council International World reports | ACI World Press release | ACI World | T1 Official | 23 Sep 2026 | 27 Sep 2026 | Report highlights paragraph; 2026 so far: turbulence beneath the surface; Montréal release lead paragraph | 3 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in gastric or oesophageal cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in gastric or oesophageal cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in ovarian, cervical or endometrial cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in ovarian, cervical or endometrial cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in urothelial or bladder cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in urothelial or bladder cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in immune thrombocytopenia or autoimmune haemolytic anaemia, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in immune thrombocytopenia or autoimmune haemolytic anaemia, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in multiple sclerosis, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in multiple sclerosis, with a start date from 2023-01-01 to 2026-09-27. | 1 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
Showing the 40 documents with the most figures for Global, of 506. Every record page names its own document; the full list is in the CSV download.
Cite this page
Data on this page is published under CC BY 4.0.
StatOrigin. (2026). Global industry statistics. Retrieved from https://statorigin.org/regions/global